115 related articles for article (PubMed ID: 23692194)
1. [A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment].
Ataoğlu MB; Atik OŞ; Gül O; Sarıkaya B; Görmeli G; Öztürk BY; Özgürol B
Eklem Hastalik Cerrahisi; 2013; 24(2):82-6. PubMed ID: 23692194
[TBL] [Abstract][Full Text] [Related]
2. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
3. Detection of post-menopausal women with low bone mineral density and elevated biochemical markers of bone turnover by panoramic radiographs.
Taguchi A; Ohtsuka M; Nakamoto T; Suei Y; Kudo Y; Tanimoto K; Bollen AM
Dentomaxillofac Radiol; 2008 Dec; 37(8):433-7. PubMed ID: 19033427
[TBL] [Abstract][Full Text] [Related]
4. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
Baxter I; Rogers A; Eastell R; Peel N
Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
[TBL] [Abstract][Full Text] [Related]
8. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
9. Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospital.
Gillett MJ; Vasikaran SD
Pathology; 2006 Feb; 38(1):49-52. PubMed ID: 16484009
[TBL] [Abstract][Full Text] [Related]
10. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
11. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
12. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
13. Course of NTX changes under continuous bisphosphonate treatment in cases of NTX over-reduction due to long-term treatment with bisphosphonates.
Iba K; Takada J; Sasaki K; Wada T; Yamashita T
J Orthop Sci; 2011 Jan; 16(1):71-6. PubMed ID: 21290152
[TBL] [Abstract][Full Text] [Related]
14. Decreased serum bone specific alkaline phosphatase and increased urinary N-terminal telopeptide of type I collagen as prognostic markers for bone mineral density loss in HIV patients on cART.
Koga I; Seo K; Yoshino Y; Kitazawa T; Kurahashi I; Ota Y
J Infect Chemother; 2016 Aug; 22(8):543-7. PubMed ID: 27346381
[TBL] [Abstract][Full Text] [Related]
15. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
Dresner-Pollak R; Karmeli F; Eliakim R; Ackerman Z; Rachmilewitz D
Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
[TBL] [Abstract][Full Text] [Related]
16. Sex steroids, biochemical markers, bone mineral density and histomorphometry in male osteoporosis patients.
Fassbender WJ; Balli M; Görtz B; Hinrichs B; Kaiser HE; Tracke HS
In Vivo; 2000; 14(5):611-8. PubMed ID: 11125545
[TBL] [Abstract][Full Text] [Related]
17. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density.
Schneider DL; Barrett-Connor EL
Arch Intern Med; 1997 Jun; 157(11):1241-5. PubMed ID: 9183236
[TBL] [Abstract][Full Text] [Related]
18. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
Sanad Z; Ellakwa H; Desouky B
Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
[TBL] [Abstract][Full Text] [Related]
19. Relationship between dental panoramic radiographic findings and biochemical markers of bone turnover.
Taguchi A; Sanada M; Krall E; Nakamoto T; Ohtsuka M; Suei Y; Tanimoto K; Kodama I; Tsuda M; Ohama K
J Bone Miner Res; 2003 Sep; 18(9):1689-94. PubMed ID: 12968679
[TBL] [Abstract][Full Text] [Related]
20. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
